Shanghai, China

Leiping Yu


 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Leiping Yu: Innovator in Pharmaceutical Compounds

Introduction

Leiping Yu is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical compounds, particularly in the development of innovative drugs related to dopamine and serotonin receptors. His work has implications for treating various diseases associated with these receptors.

Latest Patents

Leiping Yu holds a patent for a diaryl[A, G]quinolizidine compound, which includes a preparation method, pharmaceutical composition, and its uses. The invention pertains to a diarylo[a,g]quinolizidine compound of formula (I), along with its enantiomers, diastereoisomers, racemates, mixtures, pharmaceutically acceptable salts, crystalline hydrates, or solvates. This compound is particularly useful in preparing experimental model drugs related to dopamine receptors and 5-HT receptors, as well as in developing medicaments for treating or preventing diseases associated with these receptors.

Career Highlights

Throughout his career, Leiping Yu has worked with prominent organizations, including Kingsound & Partner and the Chinese Academy of Sciences. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to significant advancements in pharmaceutical research.

Collaborations

Leiping Yu has collaborated with notable colleagues such as Hong Tao Liu and Xuechu Zhen. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the pharmaceutical industry.

Conclusion

Leiping Yu is a distinguished inventor whose work in pharmaceutical compounds has the potential to advance medical treatments related to dopamine and serotonin receptors. His innovative contributions continue to shape the landscape of drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…